Atlas Trials

Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

Clinical trial NCT03768531 · WITHDRAWN

Trial details

NCT number
NCT03768531
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Resectable Biliary Tract Cancer
Start date
2019-06-14
Primary completion
2023-01-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.